Ms Lee Hye-young (49, picture), newly appointed CEO of BMS Korea, who will commence her new position on August 10 has a great career and expertise with diverse experiences.
She graduated from Seoul National University College of Pharmacy, and later obtained MBA from Korea University. She is a certified pharmacist and worked as CEO of Pfizer Singapore and vice president of Pfizer Korea.
She is a ‘healthcare expert’ who has been active in the field for over 20 years.
Her career includes CEO of Pfizer Singapore from 2015 to 2017, vice president of Pfizer Korea from 2017 – May 2019, and CEO of Pfizer Upjohn Korea from 2019 to November 2020, and has worked as CEO of Viatris Korea since November 2020.
She also has worked as a member of the executive board in the Korean Research-based Pharma Industry Association (KRPIA) since May 2021.
Starting with clinical research, business development, and strategic planning of Pfizer Korea in 2000, she moved to Shanghai and Hong Kong in 2012 and was in charge of cardiovascular treatment in the APAC region of the Pfizer’s Global Established Product (GEP) business division.
When Pfizer Upjohn is changed to the affiliation of global Viatris in November 2020, she was appointed as CEO of Viatris Korea.
Before joining Pfizer Korea, she had worked in the R&D divisions of Roche and JW Pharmaceutical.
In addition to the role of the CEO of BMS Korea, Ms Lee will also serve as the cardiovascular lead in the Asia cluster of BMS based on her experience and knowhow in the field of cardiovascular disease in Korea.
Meanwhile, Mr. Jinyoung Kim, incumbent CEO of BMS Korea is promoted to the lead of Compliance & Ethics in Global BMS.
Mr. Kim said, “I would like to express my sincere gratitude to the executives and employees who have worked hard for the growth of BMS Pharmaceutical Korea. I will actively support new CEO in my new position so that we can take another leap forward with the leadership of the new CEO, Lee Hye-young”.
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]
chop23@wikileaks-kr.org
